Pharmaceutical Industry Today

Non-Hodgkin Lymphoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

The global non-Hodgkin lymphoma market is expected to exhibit a CAGR of 8.2% during the forecast period 2024-2031. Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the body's immune system.
Published 23 February 2024

Non-Hodgkin Lymphoma Market

Global Non-Hodgkin Lymphoma Market Reaches USD 7.3 Billion in 2023, Projected to Surpass USD 13.5 Billion by 2031

Innovations in Treatment Approaches and Growing Regulatory Approvals Drive Market Growth

The global Non-Hodgkin Lymphoma Market, valued at USD 7.3 billion in 2023, is poised for significant expansion, reaching an estimated USD 13.5 billion by 2031. The market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period 2024-2031. Non-Hodgkin Lymphoma (NHL), a cancer originating in the lymphatic system, is witnessing increased attention and advancements in treatment methodologies.

To know more Insights Download Sample

NHL Market Dynamics:

The recent conditional approval by the National Medical Products Administration (NMPA) in China for AstraZeneca's Calquence (acalabrutinib) is a pivotal milestone. This approval, granted on March 23, 2023, specifically targets adult patients with mantle cell lymphoma (MCL) who have undergone at least one prior therapy. Positive results from global Phase II trials and ongoing confirmatory studies contribute to the growing regulatory support for NHL treatments. reports a Phase II clinical trial by the Abramson Cancer Center at Penn Medicine, evaluating the efficacy of RADVAX in relapsed/refractory NHL. The trial, combining pembrolizumab with low-dose radiotherapy, aims to conclude in December 2023, presenting a promising avenue for enhanced treatment options.

Challenges in the NHL Market:

Despite successes in targeted therapies, certain NHL subtypes, such as Peripheral T-cell Lymphoma (PTCL), lack specific approved treatments. This gap in targeted therapies, especially for PTCL, presents an unmet need, hindering overall market growth.

NHL Market Segment Analysis:

The market segmentation, encompassing disease type, drug class, route of administration, distribution channel, and region, reveals the dominance of B-cell lymphomas, accounting for approximately 52.6% of the market share. Rising clinical trials and investments in drugs, particularly in treating Diffuse Large B-cell Lymphoma (DLBCL), underscore the segment's significance.

Geographical Insights:

North America holds a substantial share of approximately 41.9% in the NHL market, driven by robust research and development initiatives and a well-established healthcare infrastructure. The region's focus on targeted therapy and immunotherapy, as indicated by the National Cancer Institute, positions North America as a key contributor to advancements in NHL treatment.

Market Players:

Major global players, including AbbVie, Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Roche Holding AG, Seagen, Inc., Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd., are at the forefront of driving innovations in Non-Hodgkin Lymphoma treatments.

Related Reports:

venous diseases treatment market

europe liver cancer therapeutics market

europe ovarian cancer market

europe theranostics market

dermatitis dermocosmetic products market

multiple myeloma market

About Us -

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Company Name: DataM Intelligence


Phone: +1 877 441 4866


Other Industry News

Ready to start publishing

Sign Up today!